Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry

Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry

Source: 
Endpoints
snippet: 

A partial patent invalidation by Chinese authorities has shaken the case Gilead has been building for its hep C star Sovaldi by removing a key barrier to generic entry.